anmeldenNovavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Werte in diesem Artikel
GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
Conference Details: | |||||
Presentation and Q&A | |||||
Date: | Monday, January 8, 2024 | ||||
Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | ||||
Location: | Westin St. Francis Hotel in San Francisco, California | ||||
Moderator: | Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, January 8, 2024 | ||||
Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-42nd-annual-jp-morgan-healthcare-conference-302024821.html
SOURCE NOVAVAX, INC
Ausgewählte Hebelprodukte auf Novavax
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novavax
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Novavax Aktie News
Novavax Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novavax nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.08.19 | Novavax Buy | H.C. Wainwright & Co. | |
| 11.12.18 | Novavax Outperform | Oppenheimer & Co. Inc. | |
| 29.03.18 | Novavax Buy | Seaport Global Securities | |
| 05.01.18 | Novavax Buy | B. Riley FBR, Inc. | |
| 20.09.16 | Novavax Neutral | Chardan Capital Markets |